216 related articles for article (PubMed ID: 32638150)
1. Molecular basis of the beta-lactamase protein using comparative modelling, drug screening and molecular dynamics studies to understand the resistance of β-lactam antibiotics.
Alazmi M
J Mol Model; 2020 Jul; 26(8):200. PubMed ID: 32638150
[TBL] [Abstract][Full Text] [Related]
2. Risedronate and Methotrexate Are High-Affinity Inhibitors of New Delhi Metallo-β-Lactamase-1 (NDM-1): A Drug Repurposing Approach.
Muteeb G; Alsultan A; Farhan M; Aatif M
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209073
[TBL] [Abstract][Full Text] [Related]
3. High-Throughput Virtual Screening, Molecular Dynamics Simulation, and Enzyme Kinetics Identified ZINC84525623 as a Potential Inhibitor of NDM-1.
Rehman MT; AlAjmi MF; Hussain A; Rather GM; Khan MA
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769822
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potential inhibitors against New Delhi metallo-β-lactamase-1 from natural compounds: in silico-based methods.
Salari-Jazi A; Mahnam K; Sadeghi P; Damavandi MS; Faghri J
Sci Rep; 2021 Jan; 11(1):2390. PubMed ID: 33504907
[TBL] [Abstract][Full Text] [Related]
5. Designing of inhibitors against CTX-M-15 type β-lactamase: potential drug candidate against β-lactamases-producing multi-drug-resistant bacteria.
Ali A; Danishuddin ; Maryam L; Srivastava G; Sharma A; Khan AU
J Biomol Struct Dyn; 2018 May; 36(7):1806-1821. PubMed ID: 28545327
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
7. Broad-Spectrum Inhibitors against Class A, B, and C Type β-Lactamases to Block the Hydrolysis against Antibiotics: Kinetics and Structural Characterization.
Farhat N; Gupta D; Ali A; Kumar Y; Akhtar F; Kulanthaivel S; Mishra P; Khan F; Khan AU
Microbiol Spectr; 2022 Oct; 10(5):e0045022. PubMed ID: 36069578
[TBL] [Abstract][Full Text] [Related]
8. N-(Sulfamoylbenzoyl)-L-proline Derivatives as Potential Non-β-lactam ESBL Inhibitors: Structure-Based Lead Identification, Medicinal Chemistry and Synergistic Antibacterial Activities.
Liu X; Dong S; Ma Y; Xu H; Zhao H; Gao Q
Med Chem; 2019; 15(2):196-206. PubMed ID: 30112996
[TBL] [Abstract][Full Text] [Related]
9. Non-β Lactam Inhibitors of the Serine β-Lactamase blaCTX-M15 in Drug-Resistant
Ahmad F; Parvaiz N; MacKerell AD; Azam SS
J Chem Inf Model; 2023 Nov; 63(21):6681-6695. PubMed ID: 37847018
[TBL] [Abstract][Full Text] [Related]
10. OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.
Morinaka A; Tsutsumi Y; Yamada M; Suzuki K; Watanabe T; Abe T; Furuuchi T; Inamura S; Sakamaki Y; Mitsuhashi N; Ida T; Livermore DM
J Antimicrob Chemother; 2015 Oct; 70(10):2779-86. PubMed ID: 26089439
[TBL] [Abstract][Full Text] [Related]
11. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase.
Powers RA; Blázquez J; Weston GS; Morosini MI; Baquero F; Shoichet BK
Protein Sci; 1999 Nov; 8(11):2330-7. PubMed ID: 10595535
[TBL] [Abstract][Full Text] [Related]
12. Covalent docking of selected boron-based serine beta-lactamase inhibitors.
Sgrignani J; Novati B; Colombo G; Grazioso G
J Comput Aided Mol Des; 2015 May; 29(5):441-50. PubMed ID: 25676821
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the Molecular Basis of Avibactam-Mediated Inhibition of Class A β-Lactamases.
Das CK; Nair NN
Chemistry; 2020 Aug; 26(43):9639-9651. PubMed ID: 32285965
[TBL] [Abstract][Full Text] [Related]
14. Docking and Molecular Dynamic of Microalgae Compounds as Potential Inhibitors of Beta-Lactamase.
Pestana-Nobles R; Aranguren-Díaz Y; Machado-Sierra E; Yosa J; Galan-Freyle NJ; Sepulveda-Montaño LX; Kuroda DG; Pacheco-Londoño LC
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163569
[TBL] [Abstract][Full Text] [Related]
15. Potential inhibitors designed against NDM-1 type metallo-β-lactamases: an attempt to enhance efficacies of antibiotics against multi-drug-resistant bacteria.
Khan AU; Ali A; Danishuddin ; Srivastava G; Sharma A
Sci Rep; 2017 Aug; 7(1):9207. PubMed ID: 28835636
[TBL] [Abstract][Full Text] [Related]
16. Recent research and development of NDM-1 inhibitors.
Wang T; Xu K; Zhao L; Tong R; Xiong L; Shi J
Eur J Med Chem; 2021 Nov; 223():113667. PubMed ID: 34225181
[TBL] [Abstract][Full Text] [Related]
17. Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor.
Russ D; Glaser F; Shaer Tamar E; Yelin I; Baym M; Kelsic ED; Zampaloni C; Haldimann A; Kishony R
Nat Commun; 2020 Apr; 11(1):2029. PubMed ID: 32332717
[TBL] [Abstract][Full Text] [Related]
18. Structural and Functional Aspects of Extended-Spectrum AmpC Cephalosporinases.
Powers RA
Curr Drug Targets; 2016; 17(9):1051-60. PubMed ID: 26073861
[TBL] [Abstract][Full Text] [Related]
19. Structure-based approach for identification of novel phenylboronic acids as serine-β-lactamase inhibitors.
Sgrignani J; De Luca F; Torosyan H; Docquier JD; Duan D; Novati B; Prati F; Colombo G; Grazioso G
J Comput Aided Mol Des; 2016 Oct; 30(10):851-861. PubMed ID: 27632226
[TBL] [Abstract][Full Text] [Related]
20. Binding selectivity analysis of new delhi metallo-beta-lactamase-1 inhibitors using molecular dynamics simulations: Exploring possibilities for decoding antimicrobial drug resistance.
Haque S; Ahmad F; Mathkor DM; Makhdoom H; Johargy AK; Faidah H; Babalghith AO; Jalal NA; Alhindi Z; Bantun F
J Infect Public Health; 2024 Jun; 17(6):1108-1116. PubMed ID: 38714123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
